dc.contributor
Institut Català de la Salut
dc.contributor
[Cohen JA, Bermel RA] Mellen Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. [Grossman CI] Biogen, Cambridge, MA, USA. [Hersh CM] Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, USA. [Hyland M] Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA. [Mowry EM] Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. [Tintorè M, Zabalza A, Montalban X] Servei de Neurologia i Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Cohen, Jeffrey A
dc.contributor.author
Grossman, Cynthia
dc.contributor.author
Hersh, Carrie
dc.contributor.author
Hyland, Megan
dc.contributor.author
Mowry, Ellen
dc.contributor.author
Tintore Subirana, Mar
dc.contributor.author
Zabalza de Torres, Ana
dc.contributor.author
Montalban Gairín, Xavier
dc.contributor.author
Bermel, Robert
dc.date.accessioned
2025-10-24T10:19:58Z
dc.date.available
2025-10-24T10:19:58Z
dc.date.issued
2022-09-07T12:14:43Z
dc.date.issued
2022-09-07T12:14:43Z
dc.identifier
Cohen JA, Bermel RA, Grossman CI, Hersh CM, Hyland M, Mowry EM, et al. Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions. Mult Scler J. 2022 Jun;28(7):1131–7.
dc.identifier
https://hdl.handle.net/11351/8057
dc.identifier
10.1177/13524585211061343
dc.identifier
000740936300001
dc.identifier.uri
http://hdl.handle.net/11351/8057
dc.description.abstract
Multiple sclerosis; SARS-COV-2 vaccination; Humoral immune response
dc.description.abstract
Esclerosis múltiple; Vacunación SARS-COV-2; Respuesta inmune humoral
dc.description.abstract
Esclerosi múltiple; Vacunació SARS-COV-2; Resposta immune humoral
dc.description.abstract
Background:
The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain.
Methods:
Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response.
Results:
Three hundred twenty-two people with MS were included; 91.9% received an mRNA vaccine. Post-vaccination reactive IgG rates (IgG index > 1) were 40% for anti-CD20 (32/80 patients); 41% for sphingosine 1-phosphate receptor modulators (S1PRM, 16/39); and 100% for all other classes, including the no DMT group.
Conclusion:
Anti-CD20 therapies and S1PRMs reduce IgG response to SARS-CoV-2 vaccination; IgG response is preserved with other DMTs.
dc.description.abstract
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was sponsored by Biogen (Cambridge, MA, USA). Funding for writing and editorial support was provided by Biogen.
dc.format
application/pdf
dc.publisher
SAGE Publications
dc.relation
Multiple sclerosis Journal;28(7)
dc.relation
https://doi.org/10.1177/13524585211061343
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Esclerosi múltiple - Tractament
dc.subject
Immunoglobulina G
dc.subject
COVID-19 (Malaltia) - Vacunació
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Immunoglobulin Isotypes::Immunoglobulin G
dc.subject
DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis
dc.subject
CHEMICALS AND DRUGS::Complex Mixtures::Biological Products::Vaccines::Viral Vaccines
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::isotipos de inmunoglobulinas::inmunoglobulina G
dc.subject
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::mezclas complejas::productos biológicos::vacunas::vacunas víricas
dc.title
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
